|Bid||8.59 x 800|
|Ask||34.00 x 1000|
|Day's Range||14.83 - 16.17|
|52 Week Range||9.91 - 34.02|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 10, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.17|
Subscribe to Yahoo Finance Plus to view Fair Value for TSVT
CAMBRIDGE, Mass., November 07, 2022--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the third quarter ended September 30, 2022.
CAMBRIDGE, Mass., November 03, 2022--2seventy bio, Inc. (Nasdaq: TSVT) announced today that data from two cohorts of the KarMMa-2 study of Abecma (idecabtagene vicleucel) in patients who have suboptimal response to transplant or early relapse will be presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 10-13, 2022, in New Orleans.
CAMBRIDGE, Mass. & SHANGHAI, October 27, 2022--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, today announced a strategic alliance to establish a translational and clinical cell therapy development platform designed to more rapidly explore T cell-based immunotherapy therapy products in the